ProShare Advisors’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$601K Sell
8,011
-663
-8% -$42.6K ﹤0.01% 986
2026
Q1
$489K Sell
8,674
-2,015
-19% -$131K ﹤0.01% 1081
2025
Q4
$857K Buy
10,689
+397
+4% +$26.7K ﹤0.01% 873
2025
Q3
$502K Sell
10,292
-2,274
-18% -$141K ﹤0.01% 1102
2025
Q2
$938K Sell
12,566
-318
-2% -$21.1K ﹤0.01% 841
2025
Q1
$819K Sell
12,884
-3,602
-22% -$245K ﹤0.01% 867
2024
Q4
$1.29M Buy
16,486
+4,771
+41% +$383K ﹤0.01% 821
2024
Q3
$942K Buy
11,715
+2,599
+29% +$210K ﹤0.01% 836
2024
Q2
$754K Sell
9,116
-2,374
-21% -$209K ﹤0.01% 809
2024
Q1
$981K Buy
11,490
+516
+5% +$40.5K ﹤0.01% 792
2023
Q4
$938K Buy
10,974
+1,718
+19% +$149K ﹤0.01% 769
2023
Q3
$829K Sell
9,256
-215
-2% -$19.2K ﹤0.01% 760
2023
Q2
$806K Buy
9,471
+570
+6% +$48.2K ﹤0.01% 772
2023
Q1
$737K Sell
8,901
-1,518
-15% -$123K ﹤0.01% 786
2022
Q4
$819K Buy
10,419
+1,200
+13% +$96.5K ﹤0.01% 783
2022
Q3
$681K Sell
9,219
-134
-1% -$9.62K ﹤0.01% 810
2022
Q2
$610K Sell
9,353
-5,194
-36% -$307K ﹤0.01% 877
2022
Q1
$920K Sell
14,547
-2,369
-14% -$129K ﹤0.01% 956
2021
Q4
$897K Buy
16,916
+5,724
+51% +$349K ﹤0.01% 1090
2021
Q3
$790K Sell
11,192
-7,587
-40% -$479K ﹤0.01% 991
2021
Q2
$1.25M Buy
18,779
+13,914
+286% +$985K ﹤0.01% 907
2021
Q1
$540K Sell
4,865
-24
-0.5% -$2.97K ﹤0.01% 1388
2020
Q4
$581K Buy
4,889
+590
+14% +$63.5K ﹤0.01% 1166
2020
Q3
$375K Buy
4,299
+151
+4% +$13.2K ﹤0.01% 1062
2020
Q2
$371K Sell
4,148
-1,582
-28% -$160K ﹤0.01% 1105
2020
Q1
$571K Sell
5,730
-6,719
-54% -$729K ﹤0.01% 708
2019
Q4
$1.43M Buy
12,449
+1,600
+15% +$194K 0.01% 695
2019
Q3
$1.37M Buy
10,849
+100
+0.9% +$12.7K 0.01% 673
2019
Q2
$1.29M Sell
10,749
-1,085
-9% -$107K 0.01% 682
2019
Q1
$1.03M Buy
11,834
+1,412
+14% +$128K 0.01% 746
2018
Q4
$1.04M Sell
10,422
-2,029
-16% -$213K 0.01% 694
2018
Q3
$1.43M Sell
12,451
-313
-2% -$32.4K 0.01% 684
2018
Q2
$1.15M Buy
12,764
+2,855
+29% +$241K 0.01% 782
2018
Q1
$725K Sell
9,909
-1,023
-9% -$70.2K ﹤0.01% 952
2017
Q4
$635K Buy
10,932
+5,049
+86% +$266K ﹤0.01% 1017
2017
Q3
$264K Sell
5,883
-624
-10% -$25.9K ﹤0.01% 1188
2017
Q2
$257K Sell
6,507
-1,700
-21% -$69.8K ﹤0.01% 1238
2017
Q1
$333K Sell
8,207
-1,902
-19% -$74.3K ﹤0.01% 1191
2016
Q4
$406K Buy
10,109
+3,283
+48% +$124K ﹤0.01% 1189
2016
Q3
$247K Sell
6,826
-2,268
-25% -$77.9K ﹤0.01% 1237
2016
Q2
$264K Buy
9,094
+500
+6% +$15.1K ﹤0.01% 1266
2016
Q1
$301K Sell
8,594
-2,088
-20% -$67.4K ﹤0.01% 1203
2015
Q4
$344K Buy
10,682
+2,942
+38% +$95.4K ﹤0.01% 1229
2015
Q3
$250K Sell
7,740
-2,536
-25% -$95.4K ﹤0.01% 1215
2015
Q2
$425K Sell
10,276
-3,838
-27% -$162K 0.01% 1163
2015
Q1
$634K Sell
14,114
-808
-5% -$33.8K 0.01% 1070
2014
Q4
$558K Sell
14,922
-8,503
-36% -$311K 0.01% 1142
2014
Q3
$818K Sell
23,425
-5,750
-20% -$205K 0.01% 1145
2014
Q2
$1.03M Sell
29,175
-25,517
-47% -$852K 0.01% 1145
2014
Q1
$1.78M Buy
54,692
+48,698
+812% +$1.86M 0.02% 835
2013
Q4
$253K Sell
5,994
-28,729
-83% -$1.18M ﹤0.01% 1209
2013
Q3
$1.39M Sell
34,723
-1,488
-4% -$62.4K 0.03% 634
2013
Q2
$1.5M Buy
+36,211
New +$1.47M 0.03% 607

Other funds holding HAE

ProShare Advisors's HAE Position: Q2 2026 in Review

ProShare Advisors reduced its Haemonetics (HAE) stake by 7.6% in Q2 2026, selling an estimated $42.6K and leaving 8,011 shares worth $601K. The position accounts for ﹤0.01% of the portfolio, ranked #986.

ProShare Advisors first reported a position in HAE in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.78M in Q1 2014. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • ProShare Advisors held 8,011 shares of Haemonetics worth $601K as of Q2 2026.
  • ProShare Advisors sold 663 Haemonetics shares in Q2 2026, an estimated $42.6K.
  • Haemonetics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #986 holding.
  • ProShare Advisors first reported a position in Haemonetics in Q2 2013 and has held it in 53 quarters since.
  • ProShare Advisors's Haemonetics position peaked at $1.78M in Q1 2014.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.